

# Jose Rosas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/86043/publications.pdf>

Version: 2024-02-01

20  
papers

779  
citations

840776

11  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1119  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 188-189.	0.3	0
2	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>Reumatología Clínica</i> , 2022, 18, 150-156.	0.5	44
3	Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA) <i>TJ ETQq1 1 0.784314 rgBT7Overloc</i>	0.3	12
4	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 150-156.	0.3	12
5	Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 378-385.	0.5	5
6	Practical aspects of biological trough levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 378-385.	0.3	1
7	Eficacia y seguridad de baricitinib en pacientes con artritis reumatoide y respuesta inadecuada a FAME convencionales sintéticos o biológicos: datos de un registro local. <i>Reumatología Clínica</i> , 2020, 18, 188-188.	0.5	1
8	Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. <i>Rheumatology International</i> , 2019, 39, 841-849.	3.0	15
9	ESSDAI activity index of the SJÅ–GRENSER cohort: analysis and comparison with other European cohorts. <i>Rheumatology International</i> , 2019, 39, 991-999.	3.0	9
10	Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2018, 38, 975-983.	3.0	15
11	Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. <i>Rheumatology</i> , 2018, 57, 688-693.	1.9	33
12	Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 145-148.	0.8	26
13	Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1693-1696.	0.9	71
14	SJÅ–GREN-SER: Registro nacional de pacientes con síndrome de SjÅgren primario de la Sociedad Española de Reumatología: objetivos y metodología. <i>Reumatología Clínica</i> , 2016, 12, 184-189.	0.5	12
15	Whipple's disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 165.	0.8	20
16	Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 617-23.	0.8	4
17	Estudio comparativo de las 2 versiones de un inmunoanálisis comercializado para la monitorización terapéutica de adalimumab en artritis reumatoide. <i>Reumatología Clínica</i> , 2014, 10, 105-108.	0.5	5
18	Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 942-8.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Preference and Adherence, 2013, 7, 961.	1.8	26
20	Primary Sjögren Syndrome in Spain. Medicine (United States), 2008, 87, 210-219.	1.0	459